Immunoassays detect antibodies to SARS-CoV-2 instead of identifying the live virus. According to the FDA, antibodies to SARS-CoV-2 develop approximately one to three weeks after infection and persist for a long period of time. Therefore, antibody determination is not a suitable measure to identify people who are infectious. They are not suitable to determine the difference between a sample from a person with an active infection who can spread the disease and a sample from a person who has recovered from the infection. However, they can be quite valuable as a tool for disease surveillance and investigational purposes.
PerkinElmer offers a number of different types of SARS-CoV-2 immunoassays with varied samples types, throughputs, run times, and targets. The table below will help you decide which solution best fits your needs.